In animal studies, AOD-9604 reduced body weight gain by over 50% in obese mice during a 19-day treatment period, and significantly increased fat oxidation all without affecting insulin sensitivity or glucose regulation.[1,3] A randomized controlled trial in humans found that participants taking 1 mg of AOD-9604 daily lost an average of 2.8 kg (~6 lbs) over 23 weeks, compared to 0.8 kg (~1.7 lbs) in the placebo group
Li YF, Wang W, Mayhan WG, Patel KP
Spending is anticipated to increase as manufacturers invest in outcome trials and larger production networks
At the same time, rigorous clinical trials must be designed and conducted to verify the therapys efficacy and safety, providing high-level evidence for subsequent clinical application
China has a massive population and a rising prevalence of diabetes, which makes it an important industry